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Haloperidol and olanzapine mediate metabolic
abnormalities through different molecular pathways
V Mondelli1, C Anacker1, AC Vernon2,3, A Cattaneo4, S Natesan2, M Modo2,3, P Dazzan2, S Kapur2 and CM Pariante1
The pathogenesis of antipsychotic-induced disturbances of glucose homeostasis is still unclear. Increased visceral adiposity
has been suggested to be a possible mediating mechanism. The aim of this study was to investigate, in an animal model, the
differential effects of olanzapine and haloperidol on visceral fat deposition (using magnetic resonance imaging(MRI)) and on
critical nodes of the insulin signaling pathway (liver-protein levels of IRS2 (insulin receptor substrate 2), GSK3a (glycogen
synthase kinase-3a), GSK3b, GSK3a-Ser21, GSK3b-Ser9). To this end, we studied male Sprague–Dawley rats treated with
vehicle (n¼ 8), haloperidol (2 mg kg 1 per day, n¼ 8), or olanzapine (10 mg kg 1per day, n¼ 8), using osmotic minipumps, for
8 weeks. The haloperidol group showed a higher percentage of visceral fat than both the olanzapine group and the vehicle group,
whereas there was no difference between the olanzapine and the vehicle group. In terms of insulin signaling pathway, the
olanzapine group showed significantly reduced IRS2 levels, reduced phosphorylation of GSK3a and increased phosphorylation
of GSK3b, whereas there was no difference between the haloperidol and the vehicle group. Our data suggest that different
molecular pathways mediate the disturbances of glucose homeostasis induced by haloperidol and olanzapine with a direct effect
of olanzapine on the insulin molecular pathway, possibly partly explaining the stronger propensity of olanzapine for adverse
effects on glucose regulation when compared with haloperidol in clinical settings.
Translational Psychiatry (2013) 3, e208; doi:10.1038/tp.2012.138; published online 15 January 2013
Introduction
The mortality rate of individuals with serious mental illnesses
is two to three times higher than in the general population,1
and up to 60% of the excess mortality rate in patients with
schizophrenia is attributable to physical illnesses.2 Indeed, it
is widely acknowledged that patients with schizophrenia suffer
from higher rates of metabolic syndrome and obesity-related
illnesses, such as type 2 diabetes mellitus, dyslipidaemia,
hypertension and cardiovascular disease.3 Reasons for the
increased prevalence of physical illnesses in schizophrenia
are complex, but perhaps the most important is the fact
that antipsychotic medications increases body weight and
predisposes to metabolic abnormalities.4 The molecular
mechanisms underlying these metabolic effects of antipsy-
chotics are, however, yet unclear. Moreover, there is some
evidence that olanzapine and clozapine are associated with
an increased risk for diabetes compared with other anti-
psychotics.5,6 Among the other antipsychotics, for example,
haloperidol has been less consistently associated with weight
gain and abnormal glucose regulation,4 but again, whether
olanzapine and haloperidol have different metabolic effects at
a molecular level it is not well understood yet.
One possible pathophysiological mechanism for olanza-
pine-induced hyperglycemia is the reported weight gain and/
or change in body fat distribution with a predominant visceral
fat type.7 However, previous studies in humans and rodents
have suggested that, at least for olanzapine, the effects on
glucose homeostasis and insulin sensitivity precede weight
gain and changes in visceral adipose-tissue deposition.7–10
Therefore, alternative mechanisms may occur through a
direct effect of olanzapine on humoral and/or cellular insulin
pathways, leading to impairment of insulin action, and
ultimately leading to insulin resistance.11,12
In light of this literature, we focussed our attention on the
insulin pathway. The insulin receptor, in presence of insulin,
phosphorylates insulin receptor substrate (IRS) proteins,
which are the key mediators of insulin activity. The IRS
proteins are linked to the activation of the phosphatidylinositol
3-kinase-AKT/protein kinase B pathway, which is responsible
for most of the metabolic actions of insulin, including glucose
uptake, gluconeogenesis and glycogen synthesis. Of note is
that glycogen synthase kinase-3 (GSK3), the key enzyme
involved in the regulation of glycogen synthesis, has two
isoforms, GSK3a and GSK3b. Both are constitutively active,
and their activities are primarily regulated by the phosphor-
ylation of an N-terminal serine, Ser21 of GSK3a and Ser9 of
GSK3b.13 This N-terminal phosphorylation of GSK3 results in
inhibition of its activity and a subsequent activation of the
glycogen synthase, and thereby in glycogen synthesis.13
There is evidence of antipsychotics influencing the insulin
signaling pathway in both in vivo and in vitro models,
although most of these studies have been conducted on
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brain tissue.14–16 To our knowledge, only three previous
studies have investigated the effect of antipsychotics on the
insulin signaling pathway in peripheral tissue. The first study
reported an attenuation of the insulin signaling pathway with
decreased protein levels of IRS2 in liver tissue of type 2
diabetic rats, following administration of chlorpromazine.17 A
more recent study showed an increased phosphorylation of
AKT in tibialis muscle of clozapine-treated mice.14 The third
study showed that the acute administration of olanzapine to
cultures of L6-rat skeletal muscle cells leads to an impairment
of the insulin signaling and glycogen synthesis, diminishing
insulin-stimulated AKT and GSK3a/b phosphorylation.18
Interestingly, olanzapine has been recently found to readily
fit within the binding pocket of GSK3b, suggesting a direct
effect of olanzapine on the activity of this kinase.19 When
looking at possible mechanisms mediating insulin resistance,
the study of hepatic tissue is particularly relevant, as the liver
is one of the main organs involved in the regulation of glucose
homeostasis, maintaining the normal concentration of blood
glucose through its ability to store glucose as glycogen, and
produces glucose from glycogen breakdown.20
To date, no study has investigated the effect of olanzapine
and haloperidol on visceral adipose-tissue deposition and
insulin signaling pathway in peripheral tissue in the same
animals. The aim of the present study was to investigate
molecular pathways through which antipsychotics may lead to
the development of diabetes/insulin resistance, studying the
effects of haloperidol and olanzapine in male rats on visceral
fat deposition (using magnetic resonance imaging (MRI)), and
on critical nodes of the insulin signaling pathway in the liver
(assessing liver protein levels of IRS2, GSK3a, GSK3b,
GSK3a-Ser21, GSK3b-Ser9).
Materials and methods
Animals. Twenty-four male Sprague–Dawley rats (Charles
River UK,, Kent, UK), initial body weight 240–250 g (9 weeks
of age) were housed four per cage under a 12 h light/dark
cycle (7:00 AM lights on) with food and water available ad
libitum, as previously described.21 Room temperature was
maintained at 21±2 1C and relative humidity at 55±10%.
Animal experiments were carried out with local ethical
approval and in accordance with the Home Office Animals
(Scientific Procedures) Act, UK.
Experimental design. Eight animals were treated with
vehicle, eight with haloperidol and eight with olanzapine.
Vehicle (b-hydroxypropylcyclodextrin, 20% wt/vol, acidified
by ascorbic acid to pH 6), haloperidol (2 mg kg 1 per day;
Sigma-Aldrich, Gillingham, Dorset, UK) and olanzapine
(10 mg kg 1 per day; Biophore Pharmaceuticals, Hydera-
bad, Andra Pradesh, India) were administered to the animals
using osmotic minipumps for 8 weeks (B5 human years,
considering 11.8 rat days equals 1 human year).22 The doses
of each antipsychotic were chosen based on previous D2
receptor occupancy studies in our laboratory;23 serum-
plasma levels achieved following chronic administration in
this study reflect D2 occupancy in the range of 75–90%,23
similar to clinical exposure. The osmotic pump delivers at a
steady rate in comparison to daily injections where
drug levels fall to undetectable levels within 24 h (half-
lifeo2.5 h in rats for most antipsychotics). The mean drug
plasma levels in our animals were as following: haloperidol
20.58±1.99 ng ml 1, olanzapine 60.13± 20.17 ng ml 1.
The MRI-safe osmotic minipumps (Alzet Model 2ML4, 28
days; Alzet, Cupertino, CA, USA) filled with drug or vehicle
solutions were inserted subcutaneously on the back flank
under isoflurane anesthesia (5% induction, 1.5% mainte-
nance) and replaced once after 28 days. In vivo abdominal
MRI scans were acquired after 8 weeks of antipsychotic
treatment. Animals were then killed under terminal anesthe-
sia (sodium pentobarbital, 60 mg kg 1 intraperitoneal). Liver
tissues were rapidly dissected, snap frozen in isopentane
and stored at  80 1C until further analysis could be
performed. Body weight was measured biweekly, starting
before minipump implantation until termination.
MRI acquisition and analysis. Animals were scanned after
8 weeks of treatment, and regional adiposity was determined
by calculating the cross-sectional area of fat measured on an
image slice centered at the level of the kidneys, as previously
described.24 Imaging was performed on a 7.0T horizontal
small bore magnet (Varian, Palo Alto, CA, USA) connected to
a console running VnmrJ acquisition software (v2.3; Varian).
A quadrature birdcage radiofrequency coil with 72 mm
internal diameter (Varian) was used for signal transmission
and reception. The optimal imaging protocol consisted of
coronal T2-weighted (TR 1250 ms; TE 12 ms) spin echo
images using a 256 256 matrix size, 16 averages per
phase encoding step, 10 contiguous 1-mm-thick slices, with
an in-plane spatial resolution of 625mm.
The visceral fat of the animals was measured using the
semi-automated region of interest tool in VnmrJ (Varian). At a
slice level through the middle of both kidneys (Figure 1), all
pixels were summed to yield a total body area. The fat content
within this abdominal slice was nominally ascribed to all pixels
exceeding 1s.d. greater than the signal intensity of the left
kidney.24
Western-blot analysis. To investigate changes in protein
expression of IRS2 and GSK3a/b, as well as treatment-
induced changes in GSK3a/b phosphorylation, liver tissue
was washed three times in ice cold PBS containing protease
and phosphatase inhibitors (Pierce, Rockford, IL, USA). The
washed tissue was homogenized in standard RIPA buffer
with protease and phosphatase inhibitors (Pierce) using a
dounce homogenizer, and lysed on ice for 20 min. Lysates
were centrifuged at 14 000  g for 10 min at 4 1C and the
protein-containing supernatants were used for further
analysis.
Protein concentrations were quantified using a bicincho-
ninic acid colorimetric assay system (Merck, Nottingham,
UK). Protein samples were incubated with the kit reaction
mixture in a ratio 1:8 for 30 min at 37 1C, absorbance was
measured with a microplate reader (DTX 880 Multimode
Detector, Beckman Coulter, Brea, USA) at 562 nm. The
protein concentration per sample was determined based
on a bovine serum albumin standard curve (0mg ml 1,
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1.25mg ml 1, 5 mg ml 1, 10 mg ml 1, 25 mg ml 1, 75mg ml 1,
125mg ml 1, 250mg ml 1, 500mg ml 1, 750mg ml 1).
Protein samples containing 30 mg of total protein were
boiled for 10 min at 72 1C in 1NuPAGE LDS sample buffer
(Invitrogen, Paisley, UK) and 1NuPAGE sample reducing
agent (Invitrogen), and subjected to reducing SDS-PAGE on
10% NuPAGE Bis-Tris gels for 1 h at 200V. Proteins were
electrophoretically transferred to Immuno-BlotTM PVDF mem-
branes (Bio-Rad laboratories, Hercules, CA, USA) at 110V for
1.5 h at 4 1C. Transfer efficiency was controlled by Ponceau S
staining and by pre-stained protein standards (Invitrogen).
Unspecific binding sites were blocked for 1 h in 5% bovine
serum albumin in TBS and immunoprobed with the polyclonal
rabbit anti-GSK3a (1:1000), rabbit anti-GSK3b (1:1000),
rabbit anti-GSK3a-Ser21 (1:1000), rabbit anti-GSK3b-Ser9
(1:1000) (all from Cell Signaling, Danvers, MA, USA), rabbit
anti-IRS2 (1:500; abcam, Cambridge, UK) and rabbit anti-
beta-actin antibody (1:500; Biolegend, San Diego, CA, USA)
in blocking solution at 4 1C over night. Membranes were
washed three times for 10 min in TBS containing 0.1% Tween-
20 (TBST) and incubated with a HRP-conjugated swine
antirabbit secondary antibody (1:2000; DAKO) in 5% non-fat
dry milk in TBS for 1 h at room temperature. Membranes were
washed three times for 10 min in TBST, and proteins were
visualized with enhanced chemiluminescence detection
system (GE Healthcare, Chalfont St Giles, UK).
Statistical analyses. A one-way ANOVA, followed by LSD
post-hoc tests, was used to compare weight and intra-
abdominal fat. The western blots analyses for haloperidol
and olanzapine group were run at separate times. Therefore,
we did not compare directly these two groups within a single
statistical analysis, but we used separate Mann–Whitney U
tests to compare the protein levels between the haloperidol
and the vehicle group, and the protein levels between the
olanzapine and the vehicle group. Blots for IRS2, GSK3a and
GSK3b were normalized to beta-actin. Blots for Ser21-
GSK3a and Ser9-GSK3b were normalized to unphosphory-
lated GSK3a and GSK3b, respectively. Protein levels are
presented as fold change compared with controls. Results
are presented as mean±s.e.m.
Results
Weight and visceral adipose tissue. The haloperidol
group showed a higher percentage of visceral adipose tissue
(%visceral adipose tissue 32.3±1.3) than both the olanza-
pine group (21.6±2.1; P¼ 0.002) and the vehicle group
(23.0±2.6; P¼ 0.004); there was no difference between the
olanzapine and the vehicle group (P¼ 0.7, see Figure 1).
There were no significant differences in body weight at the
end of the treatment among the three groups (haloperidol
group: 325.9±9.8 g; olanzapine group: 344.3±11.1 g; vehi-
cle group: 360.0±8.7 g, P¼ 0.07), as previously reported.21
The longitudinal change in body weight over time in the three
separate groups has been previously reported, showing
weight gain over the 8 weeks in all the three groups, with
the antipsychotic-treated animals gaining less weight com-
pared with the control group in the first 2 weeks.21
Insulin signaling pathway
IRS2. The olanzapine group showed significantly reduced
IRS2 protein levels (fold change: 0.46±0.2; P¼ 0.02) when
compared with the vehicle group. No statistical difference
was found for IRS2 protein levels between the haloperidol
and vehicle groups (fold change: 1.21±0.4; P40.05; see
Figure 2).
GSK3a and GSK3b. No significant difference was found
in the total protein levels of GSK3a and GSK3b between
the haloperidol and the vehicle group (fold change for
GSK3a: 1.53±0.3; P40.05; fold change for GSK3b:
1.34±0.2; P40.05), or between the olanzapine group and
the vehicle group (fold change for GSK3a: 0.96±0.3;
P40.05; fold change for GSK3b: 0.92±0.2; P40.05; see
Figures 3 and 4).
GSK3a-Ser21 and GSK3b-Ser9. The olanzapine group
showed a significantly reduced phosphorylation of GSK3a-
Ser21 (fold change: 0.22±0.1; P¼ 0.05) and an increased
phosphorylation of GSK3b-Ser9 (fold change: 1.93±0.3;
P¼ 0.05). We found a trend for a reduced phosphorylation of
GSK3a-Ser21 (fold change: 0.38±0.2; P¼ 0.06), but no
Figure 1 Visceral fat assessed by T2-weighted MRI in vehicle, olanzapine- and haloperidol-treated rats.
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significant difference was found in phosphorylated GSK3b-
Ser9 between the haloperidol and the vehicle group (fold
change: 1.1±0.1; P40.05; see Figures 3 and 4).
Discussion
Our findings show different molecular mechanisms underlying
the metabolic effects of olanzapine and haloperidol. We find a
direct effect of olanzapine on the hepatic insulin signaling
pathway, with a reduction in IRS2 levels in the phosphoryla-
tion of GSK3a-Ser21, and an increase in the phosphorylation
of GSK3b-Ser9, which appears in the absence of an effect on
weight or visceral adipose tissue deposition. In contrast,
haloperidol increases visceral adipose tissue deposition, but
does not significantly affect the expression of proteins
involved in the insulin signaling pathway in the liver tissue.
Our study is the first investigating the effects of olanzapine
and haloperidol on the hepatic insulin signaling pathway
in vivo. Previous studies have suggested that IRS2 is a major
player in hepatic insulin action.25 Indeed, knockdown of the
hepatic IRS2 expression leads to glucose intolerance,
whereas hepatic IRS2 overexpression attenuates gluconeo-
genesis and reduces fasting-glucose levels.26,27 In our study,
chronic treatment with olanzapine significantly decreases
hepatic levels of IRS2, suggesting that olanzapine induces
gluco-metabolic abnormalities through an inhibition of the
insulin-signaling cascade. Moreover, we find that this effect is
not associated with concurrent weight gain or increased
visceral fat deposition, supporting previous findings of an
effect of olanzapine on glucose homeostasis and insulin
sensitivity before weight gain, and/or change in body-fat
distribution.7
Indeed, and consistently with previous studies, we also did
not find an effect of antipsychotic treatment on weight in our
male rats.28–30 However, in contrast with previous findings
showing an effect of olanzapine in increasing total body or
visceral adiposity,7,31 we did not find an effect of olanzapine
on increasing visceral adipose tissue in our animals. One
possible explanation behind these differences is represented






































































































Figure 3 Hepatic levels of GSK3a, phosphorylated Ser21-GSK3a, GSK3b and phosphorylated Ser9-GSK3b in olanzapine and vehicle group. Olanzapine group showed
significantly reduced phosphorylation of GSK3a (P¼ 0.05), and increased phosphorylation of GSK3b (P¼ 0.05) when compared with vehicle group. Blots for GSK3a and
GSK3b were normalized to beta-actin. Blots for Ser21-GSK3a and Ser9-GSK3b were normalized to unphosphorylated GSK3a and GSK3b, respectively.
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antipsychotic concentration across the studies. Indeed, most
previous studies looking at antipsychotic metabolic side
effects administered antipsychotics by incorporation into the
food, and did not report plasma drug concentration.7,31
Precise regulation of a drug’s plasma concentration following
administration mixed with food or drinking water is difficult,
and therefore exposure to the antipsychotic in these models
might not reflect clinical exposure.23 Similarly to our work, only
one previous study used microinfusion pumps to achieve a
stable infusion of antipsychotics to look at olanzapine
metabolic side effects in male rats.32 Interestingly, in this
study, the authors found an increase in adiposity following
olanzapine administration.32 However, the plasma concen-
tration of olanzapine were at least three-fold higher than those
observed usually in humans in clinical settings,33,34 and than
those we had in our animals, possibly explaining the
inconsistency with our findings.
In contrast to our findings for olanzapine, we find that
haloperidol does increase visceral fat deposition, but does not
have any effect on hepatic IRS2 levels. This difference could
partly explain the difference between these two antipsychotics
in terms of association with diabetes in the clinical setting.
Interestingly, previous studies have shown that an excess of
visceral adipose tissue can lead to low-grade chronic
inflammation, dyslipidemia, insulin resistance, and ultimately,
type 2 diabetes and cardiovascular disease, possibly increas-
ing serum levels of free fatty acids, and therefore suggesting a
possible alternative pathway to diabetes onset.35
Our findings, showing an increased phosphorylation of
GSK3b in the liver tissue following treatment with olanzapine,
are consistent with previous studies in mouse brain tissue,
reporting an increased phosphorylation of GSK3b in the
cortex, hippocampus, striatum and cerebellum, upon
treatment with olanzapine.16 Indeed, this is the first study
showing this effect on peripheral tissues in vivo. Our data
appear also to be in line with evidence of a significant
elevation of liver glycogen storage in animals treated with
higher doses of olanzapine.19 However, the same findings
seem in contrast with the diminished phosphorylation of
GSK3b found by Engl et al.,18 following incubation of L6-rat
skeletal muscle cells with olanzapine in vitro. The difference
between these studies could potentially be explained by a
difference in the tissues studied. Indeed, olanzapine has been
described to acutely change insulin sensitivity in a tissue-
specific manner, decreasing insulin sensitivity in muscle
tissue, whereas either increasing or not affecting sensitivity
in adipose depots.7 We also did not find an effect of
haloperidol on hepatic phosphorylation of GSK3b. These
data are consistent with a previous study, showing a lack of
acute changes in GSK3b phosphorylation in the cortex,
hippocampus, striatum and cerebellum of mice treated with
haloperidol,16 although in contrast with another study report-
ing increased phosphorylation of both GSK3a and GSK3b in
the striatum of rats treated with haloperidol.15 Indeed, the
discrepancies with our study might be again related to the
difference in the tissues studied, as our study is the first
focussing on the insulin signaling pathway in hepatic tissue.
Our findings of increased GSK3b phosphorylation and of
decreased GSK3a phosphorylation in the olanzapine
group might initially appear conflicting, as we expected the
phosphorylation of the two GSK3 isoforms to go in the same
direction. Moreover, the increased phosphorylation of GSK3b
would suggest an increased activity of glycogen synthase,
and therefore, an increased insulin sensitivity, rather
than insulin resistance. These apparently conflicting data






























































Figure 4 Hepatic levels of GSK3a, phosphorylated Ser21-GSK3a, GSK3b and phosphorylated Ser9-GSK3b in haloperidol and vehicle group. No significant difference
was found in GSK3a, GSK3 b, or in phosphorylated Ser21-GSK3a and Ser9-GSK3b between the haloperidol and the vehicle group (P40.05). Blots for GSK3a and GSK3b
were normalized to beta-actin. Blots for Ser21-GSK3a and Ser9-GSK3b were normalized to unphosphorylated GSK3a and GSK3b, respectively.
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and tissue-specific biological roles of the two mammalian
isoforms of GSK3.36 In particular, GSK3a has a more critical
role than GSK3b in regulating hepatic glucose metabolism
and insulin sensitivity,37 whereas GSK3b is the predominant
regulator of glycogen synthase in skeletal muscles.36 In fact,
liver-specific GSK3b-knockout mice display normal metabolic
characteristics and insulin signaling.36 Therefore, we can
hypothesize that the increased hepatic phosphorylation of
GSK3b following olanzapine treatment might have a second-
ary role in the hepatic glucose metabolism that could instead
be predominantly influenced by the decreased phosphoryla-
tion of GSK3a. Indeed, future studies should focus their
attention also on proteins upstream and downstream from
GSK3 in order to obtain more detailed information about the
dysregulation of the insulin signaling cascade, following
treatment with olanzapine.
Understanding the mechanisms through which antipsycho-
tic treatment leads to increased metabolic abnormalities and
obesity-related illness is essential in order to help reducing
mortality rates, and improving quality of life for patients with
psychosis. Indeed, our study suggests that different metabolic
assessments (measurement of visceral adiposity or gluco-
metabolic assessment) and different intervention approaches
might be tailored according to the antipsychotic used.
There are few caveats in the present study. One such
limitation is that these findings do not take into account the
effect of a potential interaction between psychosis and
antipsychotic treatment on the metabolic system. Indeed,
metabolic disturbances have also been found in drug-naı¨ve
patients with first-episode psychosis, who show higher levels
of visceral fat and impaired fasting-glucose tolerance.38–40
Indeed, psychosis may predispose to metabolic abnormalities
also through a sedentary lifestyle,41 illness-related or genetic
factors,42,43 and childhood trauma.44 Further studies would
need to investigate this interaction in animal models of
schizophrenia or directly in individuals with psychosis. A
second limitation is represented by the lack of a direct
measurement of glucose tolerance and insulin activity in our
animals; future studies would need to investigate the role of
the abnormalities in the insulin signaling pathway, identified in
our study, in the development of insulin resistance. Finally, we
did not measure levels of sedation, motor function or food
intake following antipsychotic treatment; therefore, we cannot
exclude these behavioral effects as possible confounders of
our findings.
In conclusion, our data support the presence of different
molecular pathways mediating the metabolic side effects of
olanzapine and haloperidol, showing a direct effect of
olanzapine on the insulin molecular pathway, and possibly
partly explaining the stronger propensity of olanzapine for
adverse effects on glucose regulation in clinical settings. We
propose that diverse assessments and intervention
approaches for metabolic abnormalities need to be consid-
ered according to the type of antipsychotic used in patients
with psychosis.
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